Rigel R788 Raises Platelet Counts In Immune Thrombocytopenic Purpura (ITP) Patients In Phase 2 Study

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced results of its Phase 2 clinical study of R788, a novel, oral Syk kinase inhibitor, in patients with Immune Thrombocytopenic Purpura (ITP). The single-center, open-label, dose-escalating study showed that R788 (tamatinib fosdium) can improve platelet counts in this autoimmune disorder in which the body attacks and destroys its own blood platelets. [click link for full article]

More: continued here

Filed under: Blood on November 11th, 2007